Clinical Trial Update: Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study evaluating 18F-Florastamin PET/CT imaging in patients with at least intermediate risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-Florastamin PET/CT imaging (18F-Florastamin)

Snippet

Sponsor: HTA Co., Ltd. | Conditions: Prostate Cancer | Phase 3 | Status: UNKNOWN